Revista Médica del Instituto Mexicano del Seguro Social

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista Médica del Instituto Mexicano del Seguro Social >Year 2016, Issue S3

Márquez-González H, Castro-Contreras U, Cerrud-Sánchez CE, López-Gallegos D, Yáñez-Gutiérrez L
Experience in the treatment of patent ductus arteriosus closure at a mexican hospital
Rev Med Inst Mex Seguro Soc 2016; 54 (S3)

Language: Español
References: 11
Page: 291-295
PDF: 253.73 Kb.

Full text


Background: The patent ductus arteriosus (PDA) represents one of the most prevalent diseases in hospitals which treat congenital heart diseases (CHD). Currently, in groups of more than 1 year of age percutaneous closure it is the standard therapy. The aim of this paper is to determine the frequency, characteristics and treatment of PCA in congenital heart disease service at the a Cardiology Hospital in Mexico.
Methods: In clinical CHD our hospital, a descriptive study of 2010-2015 of patients who were treated with percutaneous closure PCA and surgery was performed. They were divided into the following ages: infant, preschool, children, adolescents and adults. The absolute frequencies were recorded.
Results: 187 patients of preschool and school which accounted for 60% of the total sample were obtained. Percutaneous closure catheterization was performed in 90%; 2% of complications were recorded.
Conclusions: In this clinic, the PCA is treated mostly by interventional catheterization in most stages of the human being with minimal complications.

Key words: Heart defects, congenital, Ductus arteriosus, patent, Cardiac catheterization, Thoracic surgery, Intraoperative complications.


  1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39(12): 1890-900.

  2. Dice JE, Bhatia J. Patent ductus arteriosus: An overview. J Pediatr Pharmacol Th. 2007;12(3):138-146.

  3. Sellmer A, Bjerre JV, Schmidt MR, McNamara PJ, Hjortdal VE, Host B et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed. 2013;98: F505-F510.

  4. Bose CL, Laughon MM. Patent ductus arteriosus: Lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed. 2007;92:F498-F502.

  5. Krichenko A, Benson LN, Burrows P, Möes CA, McLaughlin P, Freedom RM. Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion. Am J Cardiol. 1989;63(12):877-80.

  6. Sultan M, Ullah M, Sadiq N, Akhtar K, Akbar H. Transcatheter device closure of patent ductus arteriosus. J Coll Physicians Surg Pak. 2014;24(10):710-3.

  7. Ullah M, Sultan M, Akhtar K, Sadiq N, Akbar H. Percu taneous transcatheter PDA device closure in infancy. J Coll Physicians Surg Pak. 2014;24(8):581-5.

  8. Lamm Y, Lopushinsky S, Ma I, Dicke F, Brindle M. Treatment Options for Pediatric Patent Ductus Arteriosus. Systematic Review and Meta-analysis. CHEST. 2015;148(3):784-793.

  9. Boyalla V, Putzu P, Dierckx R, Clark A, Pellicori P. Patent ductus arteriosus in older adults: Incidental finding or relevant pathology? JAGS. 2015;63(2): 409-11.

  10. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N et al. ESC guidelines for the management of grown-up congenital heart disease. Eur Heart J. 2010;31(23):2915-57.

  11. Moore JW, Greene J, Palomares S, Javois A, Owada CY, Cheatham JP. Results of the combined U.S. Multicenter Pivotal Study and the Continuing Access Study of the Nit-Occlud PDA device for percutaneous closure of patent ductus arteriosus. JACC Cardiovasc Interv. 2014;7(12):1430-6.

>Journals >Revista Médica del Instituto Mexicano del Seguro Social >Year 2016, Issue S3

· Journal Index 
· Links 

Copyright 2019